OS Therapies Incorporated (OSTX) Stock Price & Analysis
OS Therapies Incorporated (OSTX) closed at USD 1.41 on Thursday, October 15, 2026, up 1.44% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.39; the Oct 15, 2026 session ranged USD 1.38–1.44 on volume of 375,173 shares. Market capitalization is $66.00M, with a 52-week range of USD 1.15–2.25 (ASE). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/OSTX.md
Key facts (OSTX)
- Analysts: Buy (mean 1.75 on a 1–5 scale) (4 analysts), mean target USD 8.5 (range 6–13).
- Total return with dividends: 1Y -23.8% vs S&P 500 +18.1%; 5Y -64.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-16, EPS estimate USD -0.12, revenue estimate $0K.
Analysts (OSTX)
Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 8.5 (low 6, high 13).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-09 | Roth Capital | Initiated | Buy | $7 |
Total return (dividends reinvested) (OSTX)
| 1Y (from 2025-10-16) | 5Y (from 2024-07-29) | |
|---|---|---|
| Total return | -23.8% | -64.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -23.9% | -37.6% |
| Volatility (annualized) | 73.7% | 94.6% |
| Max drawdown | -42.9% (Dec 2025→Feb 2026) | -77.1% (Dec 2024→Feb 2026) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 1.41 |
|---|---|
| Change | ▲ 1.44% (up) |
| Previous Close | USD 1.39 |
| Open | USD 1.38 |
| Day Range | USD 1.38 – 1.44 |
| 52-Week Range | USD 1.15 – 2.25 |
| Volume | 375,173 shares |
| Market Cap | $66.00M |
| Exchange | ASE |
Technical Analysis (OSTX)
Nexqual's technical model rates OSTX "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.38 (neutral) |
| vs SMA50 | Below (USD 1.64) |
| MACD | -0.06 (negative) |
Analyst Ratings (OSTX)
Wall Street analysts rate OSTX "Buy" based on 4 analysts, with a mean price target of USD 8.5 (range USD 6–13), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 8.5 |
| High Target | USD 13 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (OSTX)
| Next Earnings Date | 2026-11-16 |
|---|---|
| EPS Estimate | USD -0.12 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.2 vs est -0.23 ▲ beat |
| 2026-03-31 | USD -0.27 vs est -0.19 ▼ miss |
| 2025-12-31 | USD -0.41 vs est -0.14 ▼ miss |
| 2025-09-30 | USD -0.21 vs est -0.12 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (OSTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.18 |
| Total Cash | $205,035 |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (OSTX)
Nexqual rates OS Therapies Incorporated's overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $205K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$19M (TTM) |
| Efficiency | Mixed — No data |
Ownership (OSTX)
| Insider Ownership | +21.12% |
|---|---|
| Institutional Ownership | +6.25% |
| Shares Outstanding | 46.81M |
| Float | 40.36M |
| Short % of Float | +5.95% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (OSTX)
OS Therapies Incorporated is led by Paul A. Romness M.P.H. (age 59), Founder, Chairman, President & CEO, per Nexqual as of October 16, 2026 at 05:20 UTC.
| Founder, Chairman, President & CEO | Paul A. Romness M.P.H. (age 59) |
|---|---|
| Chief Medical Officer & Chief Scientific Officer | Robert G. Petit II (age 65) |
| Chief Financial Officer | Francis Knuettel II (age 59) |
Major Backers & Investors (OSTX)
Notable institutional backers of OS Therapies Incorporated include CM Management, LLC, Fidelity, Howard Financial Services, Ltd., according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| CM Management, LLC | 8.71% |
| Fidelity | 5.71% |
| Howard Financial Services, Ltd. | 5.4% |
| Marshall Wace LLP | 2.19% |
| HighTower Advisors, LLC | 1.86% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 37.65% |
| BlackRock | 7.67% |
| Geode Capital | 6.57% |
| State Street | 2.61% |
| Northern Trust | 1.54% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt